Inclusion Criteria:

Adult patients with untreated, locally advanced pancreatic adenocarcinoma that expresses a
GI-4000 related k-ras oncoprotein.

1. Histologically-confirmed pancreatic adenocarcinoma that expresses one of the
GI-4000-related k-ras oncoproteins (G12V, G12C, G12D, Q61L, or Q61R)

2. Locally advanced disease, (stages I-III, i.e no evidence of metastasis outside the
pancreas and its regional lymph nodes). Preferred subjects for entry into the study
are those with borderline resectable disease, as defined by:

- tumor that encases a short segment of the hepatic artery without extension to
the celiac axis and that is amenable to resection and reconstruction, OR

- tumor that abuts the superior mesenteric artery and that involves <180 degrees
of the circumference of the artery, OR

- short-segment occlusion of the superior mesenteric vein, portal vein, or their
confluence with a suitable option available for vascular reconstruction because
the veins are normal above and below the area of tumor involvement.

3. Age >18 years

4. ECOG performance status 0 or 1

5. Normal organ and bone marrow function as defined by:

Absolute neutrophil count > 1,500/μl Platelets > 100,000/μl AST(SGOT)/ALT(SGPT)< 2.5
X institutional upper limit of normal Bilirubin < 2.0 mg/dL unless due to bile duct
blockage by tumor Creatinine < 1.5 x ULN

6. A biliary stent 9F or biliary bypass before treatment, if tumor-related biliary
obstruction is present

7. The ability to sustain adequate hydration and nutrition (>1500 cal/d) by oral intake
or access for supplemental enteral feeding (nasoenteral tube, feeding jejunostomy or
PEG)

8. Patients must have measurable disease by radiographic imaging, as defined by 1 lesion
that can be accurately measured in at least one dimension (longest diameter to be
recorded) as 20 mm with conventional techniques or 10 mm with spiral CT scanning.
Marker elevation alone is insufficient for entry.

9. Ability to understand and the willingness to sign a written informed consent
documents.

10. Adequate venous or catheter access and ability to tolerate apheresis.

Exclusion Criteria:

1. Tumor metastatic to peritoneum, liver or other organs

2. Tumor that is clearly resectable for curative intent

3. Prior chemotherapy, radiation therapy, targeted therapy, or immunotherapy for
pancreatic cancer.

4. Receipt of any other investigational agents within 30 days prior to screening

5. Known HIV positive

6. A major surgical procedure or significant traumatic injury within 28 days prior to
anticipated initiation of chemotherapy, an anticipated major surgical procedure
during the course of the study, or a minor surgical procedure (laparoscopy, fine
needle aspiration, or core biopsy) within 7 days of anticipated initiation of
chemotherapy.

7. Serious non-healing wounds, ulcers, or bone fractures

8. Pregnancy or ongoing breast-feeding, as chemotherapy may pose substantial risk to the
fetus/infant.

9. Patients whose treatment plan would require treating >50% of the liver to a dose
greater than 30 Gy or treating > 50% of the total kidney volume to a dose greater
than 18 Gy

10. Positive scratch test (immediate hypersensitivity, IgE mediated) to S. cerevisiae.

11. Active autoimmune disease requiring immunosuppressive therapy